COMMUNIQUÉS West-GlobeNewswire

VALNEVA Déclaration d’actions et de droits de vote : 28 février 2026
06/03/2026
VALNEVA Déclaration d’actions et de droits de vote 28 février 2026 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : Îlot [...]
VALNEVA Declaration of shares and voting rights: February 28, 2026
06/03/2026
VALNEVA Declaration of shares and voting rights February 28, 2026 __________________________________________________________________________________________ Company name: VALNEVA Registered office: Îlot Saint-Joseph [...]
Tangram Therapeutics annonce l’administration de la première dose à un participant dans le cadre de l’essai RESTORE-MASH de phase I/II portant sur le TGM-312, un nouveau médicament expérimental à base d’ARNi
06/03/2026
L’essai RESTORE-MASH de phase I/II évaluera la sécurité, la pharmacocinétique et la pharmacodynamique du TGM-312 chez des volontaires en bonne santé et des patients atteints de MASH Les premières données sont attendues [...]
Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook
06/03/2026
ACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in [...]
Verano to Report Fourth Quarter and 2025 Full Year Financial Results on March 12th, 2026
06/03/2026
CHICAGO, March 06, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that it plans to release financial [...]
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
06/03/2026
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug Administration On-track for VLS-01 [...]
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
06/03/2026
JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027 JADE201 [...]
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
06/03/2026
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/03/2026
SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
06/03/2026
- 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival; On [...]
Prenetics Authorizes $40 Million Share Repurchase Program
06/03/2026
Management and Board Have Collectively Committed Up to $42.75 Million to Prenetics Stock Backed by $164 Million in Total Adjusted Liquidity, Zero Debt IM8 Targeting $180M to $200M in 2026 Full Year Revenue, and a Clear [...]
Anathapindika Shines Spotlight on World Sleep Day
06/03/2026
The Detox Supplement Manufacturer Connects Gut Health Resets and Brain Health to Better Sleep FORT LAUDERDALE, FL, March 06, 2026 (GLOBE NEWSWIRE) -- Sleep is a physiological requirement, and World Sleep Day emphasizes [...]
Anathapindika Spotlight Shines on Rare Disease Day (and How Detoxification Can Help)
06/03/2026
The National Observance Supports Those Managing Less-Than-Common Struggles. Anathapindika’s Supplements Can Help the Body Defend Itself. FORT LAUDERDALE, FL, March 06, 2026 (GLOBE NEWSWIRE) -- February 28th is Rare [...]
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
06/03/2026
GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/03/2026
DALLAS, March 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene [...]
Artelo Biosciences Announces Reverse Stock Split
06/03/2026
Shares Expected to Begin Trading on a Split-Adjusted Basis on March 10, 2026 SOLANA BEACH, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage [...]
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
06/03/2026
Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation Rezatapopt granted Orphan [...]
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/03/2026
BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today [...]
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
06/03/2026
Extends Company Cash Runway into Mid-2028 Financing Expected to Fund Completion of Phase 2 Ovarian Cancer Trial Financing Supports Acceleration Toward Pivotal Trial and Commercialization Financing Structured as Non- [...]

Pages